Today, March 16, 2026, investors weigh striking early colorectal cancer results against weak quarterly numbers and a finite ...

Shares of CytomX Therapeutics surged after the company reported positive data from an expanded Phase 1 trial of a colorectal cancer treatment, despite swinging to a loss in 2025. Shares were up 60% to ...

CytomX Therapeutics (NASDAQ:CTMX) outlined updated Phase 1 dose expansion results for its EpCAM-targeting Probody ...

Colorectal cancer, or cancer of the bowel or rectum, has long been associated with older adults. However, in recent years, cases among people under 50 have surged.

Investigators sought to determine whether complementary and alternative medicine (CAM) affects survival in female patients with breast cancer.

Varseta-M Phase I CRC data, response rates, safety and registrational trial plans for 2027—read key insights now.

Confirmed response rates in expansion cohorts of 32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W -- Estimated progression free survival of ...

Good news: cancer death rates in the UK have fallen to their lowest level on record. According to the latest statistics from Cancer Research UK, between 2022 and 2024, around 247 people per 100,000 ...

Their storybook romance began when Dan Gilbert, with his dashing good looks, as he jovially proclaims, stole the heart of the fair maiden and rock and roller, Lauren Gilbert. As Dan tells it, the two ...

Company shares spiked more than 60% after the therapy surpassed Wall Street benchmarks in Phase 1 testing against late-line colorectal tumors.

CytomX Therapeutics Inc. CTMX shares are up during Monday’s premarket session as the company announced positive Phase 1 ...

INDIANAPOLIS — In an encouraging 2026 Annual Report, the American Cancer Society says seven in ten people now survive their cancer diagnosis five years or more, up from just half in the mid-1970s. As ...